Back to News
Mergers & Acquisitions

Merck Expands Oncology Pipeline With ArQule

|
Published: June 22nd, 2020
The biopharmaceutical giant is paying a 107% premium for the target, which focuses on therapies for treating cancer and rare diseases.

Biopharmaceutical giant Merck & Co. Inc. (MRK) said Monday, Dec. 9, it is buying ArQule Inc. (ARQL) for $20 a share or about $2.7 billion in a move that broadens its pipeline in oncology.

The price tag marks a 107% premium over ArQule’s closing share price on Friday.

Burlington, Mass.-based ArQule focuses on therapies for treating cancer and rare diseases. The company’s lead investigational candidate, ARQ 531, is an inhibitor of an enzyme known as Bruton’s tyrosine kinase. ARQ 531 is in a Phase 2 dose expansion study to treat B-cell malignancies.

The deal announcement came on the same day that ArQule unveiled final results from a Phase 1 study of ARQ 531 at the American Society of Hematology 2019 Annual Meeting & Exposition in Orlando, Fla.

This Content is Only for The Deal Subscribers

The Deal provides actionable, intraday coverage of mergers, acquisitions and all other changes in corporate control to institutional investors, private equity, hedge funds and the firms that serve them.

If you’re already a subscriber, log in to view this article here.

More From Mergers & Acquisitions

Mergers & Acquisitions

T-Mobile/Sprint: Building the Strategy for an 'Unwinnable Case'

By Tom Terrarosa
|
Published: September 11th, 2020
In part one of The Deal’s podcast series in partnership with Cleary Gottlieb, T-Mobile and its advisers discuss the strategy to navigate the company's blockbuster deal with Sprint.
Mergers & Acquisitions

Drinks With The Deal: Cooley's Jamie Leigh

By David Marcus
|
Published: September 3rd, 2020
Cooley's Jamie Leigh discusses advising tech and life sciences companies, her work for Mirror on its agreement to sell to Lululemon and how she's staying sane in the pandemic.
Mergers & Acquisitions

Drinks With The Deal: Leo Strine Jr.

By David Marcus
|
Published: August 20th, 2020
The longtime Delaware judge discusses DuPont, Joe Biden, corporate law in the wake of Covid-19 and Thomas Cromwell on the latest Drinks With The Deal.